[HTML][HTML] Drug resistance and combating drug resistance in cancer
Cancer is the second leading cause of death in the US. Current major treatments for cancer
management include surgery, cytotoxic chemotherapy, targeted therapy, radiation therapy …
management include surgery, cytotoxic chemotherapy, targeted therapy, radiation therapy …
[HTML][HTML] A review on the effects of current chemotherapy drugs and natural agents in treating non–small cell lung cancer
CY Huang, DT Ju, CF Chang, PM Reddy… - Biomedicine, 2017 - ncbi.nlm.nih.gov
Lung cancer is the leading cause of cancer deaths worldwide, and this makes it an attractive
disease to review and possibly improve therapeutic treatment options. Surgery, radiation …
disease to review and possibly improve therapeutic treatment options. Surgery, radiation …
Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer
Although most activating mutations of epidermal growth factor receptor (EGFR)-mutant non–
small cell lung cancers (NSCLCs) are sensitive to available EGFR tyrosine kinase inhibitors …
small cell lung cancers (NSCLCs) are sensitive to available EGFR tyrosine kinase inhibitors …
Rise of deep learning for genomic, proteomic, and metabolomic data integration in precision medicine
D Grapov, J Fahrmann, K Wanichthanarak… - Omics: a journal of …, 2018 - liebertpub.com
Abstract Machine learning (ML) is being ubiquitously incorporated into everyday products
such as Internet search, email spam filters, product recommendations, image classification …
such as Internet search, email spam filters, product recommendations, image classification …
Personalised cancer medicine
SE Jackson, JD Chester - International journal of cancer, 2015 - Wiley Online Library
The evolving field of personalised medicine is playing an increasingly important role in
cancer prevention, diagnosis, prognosis and therapeutics. Its importance in clinical …
cancer prevention, diagnosis, prognosis and therapeutics. Its importance in clinical …
[HTML][HTML] EGFR inhibition blocks cancer stem cell clustering and lung metastasis of triple negative breast cancer
X Liu, V Adorno-Cruz, YF Chang, Y Jia… - Theranostics, 2021 - ncbi.nlm.nih.gov
Triple-negative breast cancer (TNBC) is one of the most aggressive and metastatic breast
cancer subtypes lacking targeted therapy. Our recent work demonstrated that circulating …
cancer subtypes lacking targeted therapy. Our recent work demonstrated that circulating …
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non–small cell lung cancer
MA Socinski, J Goldman, I El-Hariry, M Koczywas… - Clinical cancer …, 2013 - AACR
Purpose: Ganetespib is a novel inhibitor of the heat shock protein 90 (Hsp90), a chaperone
protein critical to tumor growth and proliferation. In this phase II study, we evaluated the …
protein critical to tumor growth and proliferation. In this phase II study, we evaluated the …
The role of nicotinamide in cancer chemoprevention and therapy
IP Nikas, SA Paschou, HS Ryu - Biomolecules, 2020 - mdpi.com
Nicotinamide (NAM) is a water-soluble form of Vitamin B3 (niacin) and a precursor of
nicotinamide-adenine dinucleotide (NAD+) which regulates cellular energy metabolism …
nicotinamide-adenine dinucleotide (NAD+) which regulates cellular energy metabolism …
Everything old is new again: drug repurposing approach for non-small cell lung cancer targeting MAPK signaling pathway
Non-small cell lung cancer (NSCLC) is a prominent subtype of lung carcinoma that accounts
for the majority of cancer-related deaths globally, and it is responsible for about 80% to 85 …
for the majority of cancer-related deaths globally, and it is responsible for about 80% to 85 …
A third shot at EGFR: new opportunities in cancer therapy
S Guardiola, M Varese, M Sanchez-Navarro… - Trends in …, 2019 - cell.com
Epidermal growth factor receptor (EGFR) inhibitors were among the first type of targeted
agents discovered in cancer and currently constitute the standard of care for a wide range of …
agents discovered in cancer and currently constitute the standard of care for a wide range of …